onagre commune

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Special Note

[formulation clarification]

Info: products contain varying amounts of gamma-linolenic acid, linoleic acid, other essential fatty acids

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

ADHD, peds pts

[Insufficient Evidence]

Dose: 300 mg PO bid; Info: used w/ fish oil

atopic dermatitis (eczema), adult pts

[Insufficient Evidence]

Dose: 2-3 g PO bid

atopic dermatitis (eczema), peds pts

[Insufficient Evidence]

Dose: 0.5-6 g PO qd

biliary disorders

[Insufficient Evidence]

Dose: 2 g PO bid

chronic fatigue syndrome

[Insufficient Evidence]

Dose: 72 mg gamma-linolenic acid and 510 mg linoleic acid PO qid; Info: used w/ fish oil

developmental coordination disorder, peds pts

[Insufficient Evidence]

Dose: 96 mg gamma-linolenic acid PO qd; Info: for pts 5-12 yo; used w/ fish oil

diabetic neuropathy

[Insufficient Evidence]

Dose: 360-480 mg gamma-linolenic acid PO qd

dry eye dz

[Insufficient Evidence]

Dose: 3 g PO qd

dry skin

[Insufficient Evidence]

Dose: 510 mg PO qd

dyslexia, peds pts

[Insufficient Evidence]

Dose: 96 mg gamma-linolenic acid PO qd; Info: used w/ fish oil

gestational diabetes

[Insufficient Evidence]

Dose: 1 g PO qd; Info: used w/ vitamin D

hyperlipidemia

[Insufficient Evidence]

Dose: 1.5-2 g PO bid; Alt: 250 mg PO bid

hysteroscopy

[Insufficient Evidence]

Dose: 1-2 g PV x1; Start: 2-6h before procedure

menopausal sx

[Insufficient Evidence]

Dose: 440-880 mg PO qd; Alt: 1-2 g PO qd

molluscum contagiosum, peds pts

[Insufficient Evidence]

Dose: apply oil topically bid; Info: for pts 2-10 yo

multiple sclerosis

[Insufficient Evidence]

Dose: 600-700 mg PO tid

parturition

[Insufficient Evidence]

Dose: 1 g PV x1; Info: may repeat dose q6h prn for up to 4 doses

polycystic ovary syndrome

[Insufficient Evidence]

Dose: 1 g PO qd; Info: used w/ vitamin D

postop pain

[Insufficient Evidence]

Dose: 1 g PO q30min x3 doses; Info: for postop pain after appendectomy

premenstrual syndrome

[Insufficient Evidence]

Dose: 4 g PO qd; Alt: 3 g PO qd starting day 15 of menstrual cycle until end of cycle

Raynaud phenomenon

[Insufficient Evidence]

Dose: 6 g PO qd

rheumatoid arthritis

[Insufficient Evidence]

Dose: 6 g PO qd; Alt: 2.6 g PO qd

schizophrenia

[Insufficient Evidence]

Dose: 6 g PO qd